Sweden · Delayed Price · Currency is SEK Oncopeptides AB Statistics
Total Valuation
Oncopeptides AB has a market cap or net worth of SEK 617.04 million. The enterprise value is 550.69 million.
| Market Cap | 617.04M |
| Enterprise Value | 550.69M |
Important Dates
The next confirmed earnings date is Thursday, August 27, 2026.
| Earnings Date | Aug 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Oncopeptides AB has 395.29 million shares outstanding. The number of shares has increased by 23.22% in one year.
| Current Share Class | 381.15M |
| Shares Outstanding | 395.29M |
| Shares Change (YoY) | +23.22% |
| Shares Change (QoQ) | +2.88% |
| Owned by Insiders (%) | 0.50% |
| Owned by Institutions (%) | 7.32% |
| Float | 379.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.41 |
| PB Ratio | 8.04 |
| P/TBV Ratio | 8.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.55, with a Debt / Equity ratio of 1.81.
| Current Ratio | 4.55 |
| Quick Ratio | 4.38 |
| Debt / Equity | 1.81 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -14.88 |
Financial Efficiency
Return on equity (ROE) is -623.33% and return on invested capital (ROIC) is -74.15%.
| Return on Equity (ROE) | -623.33% |
| Return on Assets (ROA) | -57.08% |
| Return on Invested Capital (ROIC) | -74.15% |
| Return on Capital Employed (ROCE) | -94.32% |
| Weighted Average Cost of Capital (WACC) | -1.00% |
| Revenue Per Employee | 1.08M |
| Profits Per Employee | -2.87M |
| Employee Count | 77 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 0.37 |
Taxes
In the past 12 months, Oncopeptides AB has paid 1.49 million in taxes.
| Income Tax | 1.49M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -54.16% in the last 52 weeks. The beta is -1.31, so Oncopeptides AB's price volatility has been lower than the market average.
| Beta (5Y) | -1.31 |
| 52-Week Price Change | -54.16% |
| 50-Day Moving Average | 1.67 |
| 200-Day Moving Average | 3.06 |
| Relative Strength Index (RSI) | 41.85 |
| Average Volume (20 Days) | 1,524,170 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Oncopeptides AB had revenue of SEK 83.24 million and -221.10 million in losses. Loss per share was -0.91.
| Revenue | 83.24M |
| Gross Profit | 80.38M |
| Operating Income | -203.34M |
| Pretax Income | -219.61M |
| Net Income | -221.10M |
| EBITDA | -201.11M |
| EBIT | -203.34M |
| Loss Per Share | -0.91 |
Balance Sheet
The company has 205.15 million in cash and 138.80 million in debt, with a net cash position of 66.35 million or 0.17 per share.
| Cash & Cash Equivalents | 205.15M |
| Total Debt | 138.80M |
| Net Cash | 66.35M |
| Net Cash Per Share | 0.17 |
| Equity (Book Value) | 76.79M |
| Book Value Per Share | 0.19 |
| Working Capital | 200.04M |
Cash Flow
| Operating Cash Flow | -200.16M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 2.23M |
| Net Borrowing | -8.16M |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 96.57%, with operating and profit margins of -244.29% and -265.63%.
| Gross Margin | 96.57% |
| Operating Margin | -244.29% |
| Pretax Margin | -263.84% |
| Profit Margin | -265.63% |
| EBITDA Margin | -241.61% |
| EBIT Margin | -244.29% |
| FCF Margin | n/a |
Dividends & Yields
Oncopeptides AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.22% |
| Shareholder Yield | -23.22% |
| Earnings Yield | -35.83% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Oncopeptides AB is 2.50, which is 60.26% higher than the current price. The consensus rating is "Hold".
| Price Target | 2.50 |
| Price Target Difference | 60.26% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 66.51% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |